COMMUNIQUÉS West-GlobeNewswire

FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’s
08/03/2024
Agency to convene an advisory committee to consider the drug WASHINGTON, March 08, 2024 (GLOBE NEWSWIRE) -- The maker of donanemab, Eli Lilly , announced today that the Food and Drug Administration (FDA) will convene an [...]
Arbutus to Participate in Two Upcoming Investor Conferences
08/03/2024
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for [...]
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
08/03/2024
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI ® ( [...]
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
08/03/2024
Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital Received $15.5 million in cash payments related to our growing [...]
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
08/03/2024
Leadership Changes Led by Appointment of Co-Founder Thomas Jensen as Interim CEO and Jeremy Graff, Ph.D., former Eli Lilly Executive, as Executive Advisor Reduced Net Loss from Operations by 50% and Reduced Net Loss by [...]
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
08/03/2024
TEL AVIV, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders [...]
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
08/03/2024
Published results show EYLEA HD with extended 12- or 16-week dosing regimens demonstrated non-inferior vision gains to standard of care EYLEA ® (aflibercept) Injection 2 mg with fixed 8-week dosing in patients with wAMD [...]
Bio-Path Holdings Reports Full Year 2023 Financial Results
08/03/2024
Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, March 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and [...]
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
08/03/2024
HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on [...]
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
08/03/2024
Data adds to increasing body of evidence supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease [...]
As part of International Women’s Day 2024, Women’s Health Advocate calls on expeditious passage of C-64: An Act Respecting Pharmacare
08/03/2024
OTTAWA, March 08, 2024 (GLOBE NEWSWIRE) -- The Society of Obstetricians and Gynaecologist of Canada (SOGC) recognizes and celebrates the incredible contributions of women in Canadian society part International Women’s [...]
Dans le cadre de la Journée internationale des femmes de 2024, les professionnels de la santé des femmes demandent à ce que le projet de loi C-64, Loi concernant l’assurance médicaments, soit adopté rapidement
08/03/2024
OTTAWA, 08 mars 2024 (GLOBE NEWSWIRE) -- En cette Journée internationale des femmes, la Société des obstétriciens et gynécologues du Canada (SOGC) reconnaît et célèbre la contribution incroyable des femmes pour la [...]
Augmedix to Announce Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024
08/03/2024
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions, announced today it will [...]
Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
08/03/2024
GAL-201 specifically targets and binds to misfolded Aβ monomers, preventing their aggregation to toxic Aβ oligomers and protofibrils As a consequence, consistent beneficial effects have been demonstrated on synaptic [...]
Crossject gender equality score reaches 96/100 in 2024
08/03/2024
Dijon, France, March 8, 2024 – 7:30 pm CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, today announces its EU Gender [...]
Le Score de l’index Egalité femmes-hommes chez Crossject atteint 96/100 en 2024
08/03/2024
Dijon, France, 08 mars 2024 – 07:30 CET - Crossject (ISIN : FR0011716265 ; Euronext : ALCJ), une société pharmaceutique spécialisée qui développe des auto-injecteurs sans aiguille dédiés aux situations d’urgence, [...]
Hyloris to Report 2023 Full-Year Results on 14 March 2024
08/03/2024
Liège, Belgium – 08 February 2024, 07:00 AM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) , a specialty biopharma company committed to addressing unmet medical needs through [...]
Hyloris Annonce ses Résultats Financiers Annuels le 14 mars 2024
08/03/2024
Liège, Belgique – le 8 mars 2024, 07:00 heures CET - Information non réglementée - Hyloris Pharmaceuticals SA (Euronext Bruxelles : HYL), une société biopharmaceutique spécialisée qui s'engage à répondre à des besoins [...]
Mithra reports full year 2023 financial results
08/03/2024
Mithra reports full year 2023 financial results Revenues were EUR 40.2 million, down from the 2022 result of EUR 67.0 million which was positively impacted by exceptional upfront cash payments from partnerships. Product [...]

Pages